CTLA4 and hereditary clear cell renal cell carcinoma: demonstrated improvement in the rate of survival of non-small cell lung cancer, renal cell carcinoma, melanoma, and head and neck squamous cell cancer by blocking the CTLA-4 immune checkpoint, which showed that the CTLA-4 gene is a promising target gene in the future treatment for cancer (107).